Category Archives: Pr Newswire

This Valentine’s Day, Oxford Treatment Center Underscores the Power of Couples Recovery

ETTA, Miss., Feb. 12, 2026 (GLOBE NEWSWIRE) — As Valentine’s Day approaches, Oxford Treatment Center emphasizes the critical role of joint recovery for couples affected by substance misuse, offering a specialized couples rehab program at its Etta campus to address the unique challenges these partnerships face. When both partners are struggling with substance use, the impact […]

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before […]

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will […]

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”,HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical […]

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

– Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam. NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the […]

Uluṟu’s Global Art Icon ‘Field of Light’ Marks 10 Years with Public Celebrations

Bruce Munro’s original installation reaches 750,000 visitors as new art, guest experiences and cultural collaborations are unveiled by Ayers Rock Resort, Uluṟu. SYDNEY, Feb. 13, 2026 /PRNewswire/ — One of the world’s most recognisable large-scale light installations, Bruce Munro’s Field of Light, marks its 10th anniversary in 2026, celebrated with events and collaborations across Australia. Opening in […]

Cboe Launches Nearly 24-Hour Trading in Russell 2000 Index Options

Cash-settled Russell 2000® Index (RUT) options now available during Cboe’s Global Trading Hours Cboe now offers nearly 24×5 trading for RUT, S&P 500 Index and Cboe Volatility Index options RUT options and Cboe’s Global Trading Hours both reached record volumes in 2025 CHICAGO, Feb. 13, 2026 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s […]

Elliott Management Statement on Toyota Industries Corporation

Elliott does not intend to tender its shares into the Extended TOB at the current terms Elliott strongly encourages other shareholders not to tender and to withdraw any shares already tendered LONDON, Feb. 13, 2026 /PRNewswire/ — Elliott Investment Management L.P. and Elliott Advisors (UK) Limited (“Elliott”), which advise funds that together have a significant investment […]

NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Aarhus, Denmark, 12 February 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announced that top-line data results from its Phase 2a SYNAPSE-CMT study evaluating ignaseclant (formerly known as NMD670) in patients living with Charcot-Marie-Tooth disease (CMT) types 1 or 2 has been accepted […]

PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner

Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease Network MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® […]